NCT06193421View on ClinicalTrials.gov

High-Dose Ambroxol in GBA1-Related Parkinson

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

February 27, 2025

Study Completion Date

April 30, 2025

Conditions
Parkinson DiseaseGBA Gene Mutation
Interventions
DRUG

Ambroxol Hydrochloride

75mg slow release (SR), X16/day or 300mg X4/day oral capsules.

Trial Locations (1)

9103102

RECRUITING

Shaare Zedek Medical Center, Jerusalem

Sponsors

Lead Sponsor

Agyany Pharma LTD
All Listed Sponsors
lead

Agyany Pharma LTD

INDUSTRY

NCT06193421 - High-Dose Ambroxol in GBA1-Related Parkinson | Biotech Hunter | Biotech Hunter